Executives at medical imaging software company Vital Images confirmed Feb. 11 the bad news they told investors in early January: that revenues fell in the fourth quarter of 2003. The news, released Jan. 8, caused at that time a seven-point drop in the
Executives at medical imaging software company Vital Images confirmed Feb. 11 the bad news they told investors in early January: that revenues fell in the fourth quarter of 2003. The news, released Jan. 8, caused at that time a seven-point drop in the company's $20 per share stock price. Share prices recovered slightly but then continued to slide after the February release of detailed financial information, despite company efforts to highlight a 27% rise in total revenue during 2003 to $26.8 million from $21.1 million and a 36% growth in 2003 cash flow. A dominant concern was the drop in revenues from $6.2 million in the previous year's fourth quarter to $5.2 million in 4Q 2003 and a drop in net income in 4Q quarter to $7000 from $416,000 in the year earlier period. The company attributed the sales slowdown to several factors, including sluggishness in CT scanner purchases and the growing integration of 3D post-processing capabilities with PACS.
Company strategists are trying to turn the trend toward 3D/PACS integration to their advantage. In early January, Vital Images signed a definitive agreement to acquire Hinnovation, a private Milwaukee-based provider of software solutions that allow physicians to use low-end PCs or notebook computers to access 2D, 3D, and 4D medical applications securely over the Internet. Vital Images expects to close the transaction this month. Executives at Vital Images also hope to benefit from a joint PACS distribution agreement with McKesson Information Solutions.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.